Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 50%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics has demonstrated significant momentum with a projected acceleration in procedure volumes exceeding 50% year-over-year by the second half of 2026, driven by effective commercial initiatives. The company recently reported strong quarterly placements of capital systems, achieving 58 installations, which surpassed previous guidance and reflects a robust demand in the face of a challenging macroeconomic environment. With Q3'25 sales of $83.3 million, representing a 43% year-over-year increase, Procept BioRobotics not only surpassed revenue expectations but also showcased the potential for sustainable double-digit growth, particularly in benign prostatic hyperplasia treatments through increased utilization and new surgery centers.

Bears say

PROCEPT BioRobotics Corp has experienced a significant negative outlook due to its fourth-quarter revenue falling 19% below consensus expectations, coupled with a downward revision of fiscal year 2026 sales guidance that is 5% lower than market consensus. The company noted challenges in handpiece sales resulting from the removal of price discounts for bulk purchases and inventory de-stocking, which further exacerbates its financial difficulties. Additionally, external pressures on hospitals related to profitability following COVID-19 and broader macroeconomic disruptions contribute to concerns regarding the company's future growth projections and overall market performance.

PRCT has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 10 analysts, PRCT has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.